Astaxanthin Supplementation Assists Sorafenib in Slowing Skeletal Muscle Atrophy in H22 Tumor‐Bearing Mice via Reversing Abnormal Glucose Metabolism
Molecular Nutrition & Food Research · 2023
DOI: 10.1002/mnfr.202300076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, 2023. Verfasst von Pengfei Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Food Science and Human Health, College of Food Science and Engineering, Ocean University of China, Qingdao, Shandong, 266003, China. Hauptthemen laut MEDLINE: Cachexia, Glucose. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Scope Cachexia, which is often marked by skeletal muscular atrophy, is one of the leading causes of death in cancer patients. Astaxanthin, a carotenoid obtained from marine organisms that can aid in the prevention and treatment of a variety of disorders. In this study, to assess whether astaxanthin ameliorates weight loss and skeletal muscle atrophy in sorafenib‐treated hepatocellular carcinoma mice is aimed. Methods and results H22 mice are treated with 30 mg kg −1 day −1 of sorafenib and 60 mg kg −1 day −1 of astaxanthin by gavage lasted for 18 days. Sorafenib does not delay skeletal muscle atrophy and weight loss, although it does not reduce tumor burden. Astaxanthin dramatically delays weight loss and skeletal muscle atrophy in sorafenib‐treating mice, without affecting the food intake. Astaxanthin inhibits the tumor glycolysis, slows down gluconeogenesis, and improves insulin resistance in tumor‐bearing mice. Astaxanthin increases glucose competition in skeletal muscle by targeting the PI3K/Akt/GLUT4 signaling pathway, and enhances glucose utilization efficiency in skeletal muscle, thereby slowing skeletal muscle atrophy. Conclusion The findings show the significant potential of astaxanthin as nutritional supplements for cancer patients, as well as the notion that nutritional interventions should be implemented at the initiation of cancer treatment, as instead of waiting until cachexia sets in.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Food Science and Human Health, College of Food Science and Engineering, Ocean University of China, Qingdao, Shandong, 266003, China.
- Laboratory of Marine Drugs and Biological Products, Pilot National Laboratory for Marine Science and Technology, Qingdao, Shandong, 266235, China.
ORCID-Profile: Qingjuan Tang, Jie Xu, Yuming Wang
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Ren, P., Yu, X., Tang, Q., Huan, Y., Xu, J., Wang, Y., & Xue, C. (2023). Astaxanthin Supplementation Assists Sorafenib in Slowing Skeletal Muscle Atrophy in H22 Tumor‐Bearing Mice via Reversing Abnormal Glucose Metabolism. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.202300076
Vancouver
Ren P, Yu X, Tang Q, Huan Y, Xu J, Wang Y, et al. Astaxanthin Supplementation Assists Sorafenib in Slowing Skeletal Muscle Atrophy in H22 Tumor‐Bearing Mice via Reversing Abnormal Glucose Metabolism. Molecular Nutrition & Food Research. 2023. doi:10.1002/mnfr.202300076
BibTeX
@article{Ren2023,
author = {Ren, Pengfei and Yu, Xinyue and Tang, Qingjuan and Huan, Yuchen and Xu, Jie and Wang, Yuming and Xue, Changhu},
title = {Astaxanthin Supplementation Assists Sorafenib in Slowing Skeletal Muscle Atrophy in H22 Tumor‐Bearing Mice via Reversing Abnormal Glucose Metabolism},
journal = {Molecular Nutrition & Food Research},
year = {2023},
doi = {10.1002/mnfr.202300076}
}
EUVIMED